B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

STK16

MOLECULAR TARGET

serine/threonine kinase 16

UniProt: O75716NCBI Gene: 857610 compounds

STK16 (serine/threonine kinase 16) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting STK16

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Quercetin1.102
2sp6001251.102
3Apigenin 5,7,4'-trihydroxy-flavone,0.691
4chrysin0.691
5fisetin0.691
6Kaempferols0.691
7Luteolin 5,7,3',4'-tetrahydroxy-flavone,0.691
8Axitinib0.691
9pictilisib0.691
10Sorafenib0.691

About STK16 as a Drug Target

STK16 (serine/threonine kinase 16) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented STK16 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

STK16 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.